HO-1 drives autophagy as a mechanism of resistance against HER2-targeted therapies
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-7217
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
HO-1 drives autophagy as a mechanism of resistance against HER2-targeted therapies ; volume:179 ; number:3 ; day:8 ; month:11 ; year:2019 ; pages:543-555 ; date:2.2020
Breast cancer research and treatment ; 179, Heft 3 (8.11.2019), 543-555, 2.2020
- Urheber
-
Tracey, Natasha
Creedon, Helen
Kemp, Alain J.
Culley, Jayne
Muir, Morwenna
Klinowska, Teresa
Brunton, Valerie G.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s10549-019-05489-1
- URN
-
urn:nbn:de:101:1-2020050322562701514006
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:02 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Tracey, Natasha
- Creedon, Helen
- Kemp, Alain J.
- Culley, Jayne
- Muir, Morwenna
- Klinowska, Teresa
- Brunton, Valerie G.
- SpringerLink (Online service)
Ähnliche Objekte (12)
HER2-targeted therapies in cancer: a systematic review
Targeted therapies for ER+/HER2- metastatic breast cancer
Recombinant immunotoxins development for HER2-based targeted cancer therapies
HER2 dynamics and EGF-NRG1 shape the response of HER2-targeted therapies in breast cancer
Rational Design of HER2-Targeted Combination Therapies to Reverse Drug Resistance in Fibroblast-Protected HER2+ Breast Cancer Cells
Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer
Targeted therapies for cancer
The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer – a systematic review
"Targeted therapies" beim nichtkleinzelligen Bronchialkarzinom
Targeted therapies for myeloproliferative neoplasms
Targeted Therapies in Pediatric Oncology
Gasdermin B over-expression modulates HER2-targeted therapy resistance by inducing protective autophagy through Rab7 activation
HER2-targeted therapies in cancer: a systematic review
Targeted therapies for ER+/HER2- metastatic breast cancer
Recombinant immunotoxins development for HER2-based targeted cancer therapies
HER2 dynamics and EGF-NRG1 shape the response of HER2-targeted therapies in breast cancer
Rational Design of HER2-Targeted Combination Therapies to Reverse Drug Resistance in Fibroblast-Protected HER2+ Breast Cancer Cells
Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer
Targeted therapies for cancer
The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer – a systematic review
"Targeted therapies" beim nichtkleinzelligen Bronchialkarzinom
Targeted therapies for myeloproliferative neoplasms
Targeted Therapies in Pediatric Oncology
Gasdermin B over-expression modulates HER2-targeted therapy resistance by inducing protective autophagy through Rab7 activation
HER2-targeted therapies in cancer: a systematic review
Targeted therapies for ER+/HER2- metastatic breast cancer
Recombinant immunotoxins development for HER2-based targeted cancer therapies
HER2 dynamics and EGF-NRG1 shape the response of HER2-targeted therapies in breast cancer
Rational Design of HER2-Targeted Combination Therapies to Reverse Drug Resistance in Fibroblast-Protected HER2+ Breast Cancer Cells
Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer
Targeted therapies for cancer
The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer – a systematic review
"Targeted therapies" beim nichtkleinzelligen Bronchialkarzinom
Targeted therapies for myeloproliferative neoplasms
Targeted Therapies in Pediatric Oncology